Risk stratification in early breast cancer in premenopausal and postmenopausal women integrating genomic assays with clinicopathological featuresSestak, IvanaCurrent Opinion in Oncology: January 2019 - Volume 31 - Issue 1 - p 29–34 doi: 10.1097/CCO.0000000000000490 BREAST CANCER: Edited by Giuseppe Curigliano Abstract Author InformationAuthors Article MetricsMetrics Purpose of review There is growing consensus that genomic assays provide useful complementary information to clinicopathological features in oestrogen receptor-positive breast cancers. Here, ongoing research with multigene tests used for postmenopausal breast cancer and new emerging prognostic and predictive markers for pre and postmenopausal women are summarised. Recent findings Results of the TAILORx trial have shown that women with an intermediate risk score do not benefit from adjuvant chemotherapy. Prosgina has been further investigated in a contemporary patient population in postmenopausal women and its use has been extended for premenopausal women. The EndoPredict was extensively used in decision-impact studies showing that its use can potentially reduce the need for adjuvant chemotherapy. Several new genomic assays have been developed, with some of them showing promising use for women with early oestrogen receptor-positive breast cancer. Summary New areas of research for prediction of recurrence and risk stratification involve the development of immune gene signatures that carry modest but significant prognostic value. The recent expansion of high-throughput technology platforms including circulating tumour DNA/RNA and microRNA offer new opportunities to improve prediction models, particularly in women with oestrogen receptor-negative disease and premenopausal women. Genomic assays have clearly improved prognostication of early oestrogen receptor-positive breast cancer but it is clear that standard clinicopathological parameters are still very important when identifying patient for adjuvant chemotherapy. Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University London, London, UK Correspondence to Ivana Sestak, PhD, Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University London, Charterhouse Square, London, EC1M 6BQ, UK. Tel: +44(0)2078823522; e-mail: email@example.com Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.